-
Immunovant NASDAQ:IMVT Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Location: | Website: immunovant.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.91B
Cash
472.9M
Avg Qtr Burn
-67.91M
Short % of Float
18.67%
Insider Ownership
67.23%
Institutional Own.
54.57%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Batoclimab (IMVT-1401) Details Thyroid Eye Disease | Phase 3 Data readout | |
Phase 3 Data readout | ||
Batoclimab (IMVT-1401) Details Graves’ disease | Phase 3 Update | |
IMVT-1402 Details Graves’ disease | Phase 3 Initiation | |
Batoclimab (IMVT-1401) Details Chronic inflammatory disorder | Phase 2b Data readout | |
IMVT-1402 Details Autoimmune disease, Warm autoimmune hemolytic anemia | Phase 1 Update | |
Batoclimab (IMVT-1401) Details Warm autoimmune hemolytic anemia | Failed Discontinued |